Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland · Delayed Price · Currency is CHF 51.90
-0.30 (-0.57%)
Jul 31, 2026, 5:30 PM CET
Basilea Pharmaceutica AG Ratios and Metrics
Market cap in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 643 | 672 | 501 | 424 | 547 | 485 | |
Market Cap Growth | -8.48% | 34.07% | 18.37% | -22.60% | 12.96% | -16.11% |
Enterprise Value | 572.77 | 761.57 | 613.16 | 552.26 | 734.51 | 608.53 |
Last Close Price | 51.90 | 54.70 | 41.35 | 35.30 | 45.80 | 40.92 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.52 | 17.42 | 7.09 | 41.05 | 44.90 | - |
Forward PE | 10.81 | 13.26 | 10.63 | 15.17 | 98.35 | 225.87 |
PEG Ratio | - | 0.25 | 0.38 | 0.13 | - | - |
PS Ratio | 2.77 | 2.89 | 2.40 | 2.69 | 3.70 | 3.27 |
PB Ratio | 5.03 | 5.26 | 6.19 | -42.35 | -26.42 | -8.27 |
P/TBV Ratio | 5.57 | 5.87 | 7.11 | - | - | - |
P/FCF Ratio | 10.82 | 11.31 | 6.90 | 31.54 | 139.71 | - |
P/OCF Ratio | 10.36 | 10.83 | 6.74 | 29.74 | 77.58 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.46 | 3.28 | 2.94 | 3.50 | 4.97 | 4.11 |
EV/EBITDA Ratio | 10.73 | 14.27 | 9.75 | 26.57 | 37.40 | 313.51 |
EV/EBIT Ratio | 11.11 | 14.77 | 10.02 | 28.76 | 39.61 | 512.66 |
EV/FCF Ratio | 9.63 | 12.81 | 8.44 | 41.12 | 187.47 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.68 | 0.68 | 1.35 | -11.11 | -7.13 | -1.61 |
Debt / EBITDA Ratio | 1.67 | 1.67 | 1.78 | 6.19 | 9.53 | 112.81 |
Debt / FCF Ratio | 1.50 | 1.50 | 1.54 | 9.57 | 47.76 | - |
Net Debt / Equity Ratio | 0.70 | 0.70 | 1.38 | -12.86 | -9.03 | -2.12 |
Net Debt / EBITDA Ratio | 1.67 | 1.67 | 1.78 | 6.19 | 9.53 | 63.86 |
Net Debt / FCF Ratio | 1.50 | 1.50 | 1.54 | 9.57 | 47.76 | -3.80 |
Asset Turnover | 0.86 | 0.86 | 0.97 | 0.80 | 0.63 | 0.62 |
Inventory Turnover | 1.48 | 1.48 | 1.33 | 1.06 | 1.05 | 1.09 |
Quick Ratio | 1.29 | 1.29 | 1.28 | 1.22 | 0.82 | 0.91 |
Current Ratio | 5.11 | 5.11 | 4.85 | 3.20 | 2.34 | 1.38 |
Return on Equity (ROE) | 38.52% | 38.52% | 218.58% | -68.04% | -30.63% | 8.50% |
Return on Assets (ROA) | 16.75% | 16.75% | 36.55% | 9.74% | 7.95% | 0.50% |
Return on Invested Capital (ROIC) | 20.82% | 22.07% | 49.49% | 14.12% | 17.01% | 0.95% |
Return on Capital Employed (ROCE) | 23.17% | 23.17% | 36.21% | 14.14% | 16.95% | 0.94% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.25% | 5.74% | 14.10% | 2.44% | 2.23% | - |
FCF Yield | 9.24% | 8.85% | 14.49% | 3.17% | 0.72% | - |
Buyback Yield / Dilution | 1.23% | 1.23% | -14.10% | -1.67% | -2.24% | -13.62% |
Total Shareholder Return | 1.23% | 1.23% | -14.10% | -1.67% | -2.24% | -13.62% |